CMS is trying to make a 2-sided risk model in the Oncology Care Model enticing for practices, but there is still a lot of math practices need to work out before making the decision, said Blase Polite, MD, associate professor of medicine and the executive director for accountable care at the University of Chicago.
CMS is trying to make a 2-sided risk model in the Oncology Care Model enticing for practices, but there is still a lot of math practices need to work out before making the decision, said Blase Polite, MD, associate professor of medicine and the executive director for accountable care at the University of Chicago.
Transcript
Will the adjustments CMS has made for practices to take on 2-sided risk in the Oncology Care Model make a difference?
I think they are clearly trying to do everything possible to entice practices in and there have been very nice moves. I think there are more practices considering 2-sided risk than I would have predicted 2 or 3 years ago. So, I do think that they’re going to get a larger number than, again, I think they would have expected.
They’re trying to be as accommodating as possible because I know from their standpoint, having people who are interested in a 2-sided risk model is very, very important for them to be able to show that this is a feasible model going forward. So, they seem to be bending over backwards to get people enticed into the 2-sided risk model.
Our institute and others around the country are still running the numbers, there’s still al ittle bit of confusion of exactly how the math works out in the model, and what’s included in there. But, I think as people start running the numbers, to the extent that people will get the 5% bonus, the [Merit-based Incentive Payment System] bonus from being an advanced practice [alternative payment model], I think all those things make it more and more enticing to do a 2-sided risk model.
Now, on the other hand, there are those who do say, “Should we be rewarding CMS for a model that many consider flawed? And if by going into 2-sided risk, are we essentially voting with our approval, by doing 2-sided risk, that we’re happy with the model?” So, I know there is tension in the community on that side.
But they clearly are doing everything they can to get us into a 2-sided risk model.
Real-World Data Show Sotorasib Effective for NSCLC With KRAS Mutation
May 18th 2024Data from real-world and clinical-trial settings on frontline monotherapy treatment with the KRAS inhibitor sotorasib both show similar progression-free survivals and a high likelihood that the treatment’s efficacy is not affected with dose reduction.
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Study Highlights Significant Increases in Utilization, Spending on DMD Drugs in Medicaid
May 17th 2024The findings add to recent research on the growing utilization, expenditure, and prices of Duchenne muscular dystrophy (DMD) therapies in the current landscape, an area health care policy could potentially address.
Read More
CMS Medicare Final Rule: Advancing Benefits, Competition, and Consumer Protection
May 7th 2024On this episode of Managed Care Cast, we're talking with Karen Iapoce, senior director of government products and programs at ZeOmega, about the recent CMS final rule on Medicare Part D and Medicare Advantage.
Listen
Perioperative Nivolumab Boosts NSCLC Survival: CheckMate 77T Trial
May 16th 2024This interim analysis of the CheckMate 77T trial, outcomes were compared between adult patients receiving neoadjuvant nivolumab plus chemotherapy or neoadjuvant chemotherapy plus placebo for resectable non–small cell lung cancer (NSCLC).
Read More
ATS 2024: Bridging the Past, Present, and Future of Respiratory Care
May 16th 2024The application of artificial intelligence in medicine is anticipated as a highlight of ATS 2024, with sessions exploring its applications in research, radiological interpretation, and pediatric pulmonology.
Read More